Valion Bio, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Valion Bio, Inc. on August 26, 2026. The filing announces a material modification to the rights of security holders via a reverse stock split. The Company is an emerging growth company incorporated in Delaware and listed on The Nasdaq Capital Market under the symbol "VBIO."
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on corporate governance and capital structure adjustments.
Material Changes
- Reverse Stock Split: The Board of Directors approved a 1-for-25 reverse stock split of the Company's common stock.
- Effective Date: The split is scheduled to become effective at 12:01 a.m. Eastern Time on August 31, 2026.
- Reason for Action: The split is intended to regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. The Company received a non-compliance notification on March 19, 2026, and has until September 15, 2026, to comply.
- Shareholder Impact:
- Outstanding shares will be divided by 25.
- Fractional shares will not be issued; instead, they will be rounded up to the nearest whole share.
- Options, warrants, and convertible securities will be adjusted by dividing share counts by 25 and multiplying exercise/conversion prices by 25.
- The CUSIP number will change to 918942202, while the trading symbol "VBIO" remains unchanged.
Guidance, Outlook, and Risks
Management expects the reverse split to increase the closing bid price above the $1.00 threshold, thereby maintaining the Company's Nasdaq listing. However, the filing explicitly states that no assurances can be provided regarding the effectiveness of the split in achieving this goal. The document includes standard forward-looking statement disclaimers regarding risks related to the split's impact on stock price, potential dilution from rounding fractional shares, and the ability to maintain listing status.
Investor Verification Checklist
- Verify the effective date of the reverse split (August 31, 2026) and the new CUSIP number (918942202).
- Confirm the treatment of fractional shares (rounded up to the nearest whole share) and its potential impact on total share count.
- Monitor the stock price post-split to determine if the $1.00 minimum bid price requirement is met by the September 15, 2026 deadline.
- Review the adjustment of exercise prices for any outstanding options or warrants held.